Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Candidate Fizurex™
Altasciences has announced the successful completion of a pivotal toxicology study for Steel Therapeutics Inc.’s lead investigational therapy, Fizurex™, marking an important step toward clinical development of a potential new treatment for anal fissures. The achievement represents a key regulatory milestone for the program, providing the safety data required to support an upcoming Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA).
The Good Laboratory Practice (GLP)-compliant toxicology study demonstrated a favorable safety profile for Fizurex™, enabling Steel Therapeutics to advance preparations for filing its IND application during the third quarter of 2026. If the FDA accepts the application, the company plans to begin first-in-human clinical trials in 2027, bringing the investigational therapy one step closer to patients.
Advancing a New Treatment for Anal Fissures
Anal fissures are small tears in the lining of the anal canal that can cause severe pain, bleeding, and discomfort during bowel movements. Although the condition affects a significant number of patients, available treatment options remain limited and are often inconsistent in their effectiveness. Many patients rely on compounded topical medications or undergo surgical intervention when conservative therapies fail.
Steel Therapeutics developed Fizurex™ with the goal of addressing these treatment challenges by creating a standardized, easy-to-use therapy that could offer reliable clinical performance while improving patient convenience.
The investigational product is a patent-pending, single-use topical wipe specifically designed for the treatment of anal fissures. Unlike compounded medications, which may vary in formulation and preparation depending on the pharmacy, Fizurex™ aims to provide a consistent dosage and formulation that can be evaluated through the FDA’s regulatory pathway.
The product concept builds upon years of clinical experience with compounded prescriptions while moving toward a commercially manufactured pharmaceutical product supported by comprehensive scientific evidence and regulatory review.
Importance of the Toxicology Study
Before an investigational therapy can enter human clinical trials in the United States, developers must complete a series of nonclinical studies that evaluate the product’s safety. These studies are essential components of an IND submission and help regulators determine whether the therapy can be tested safely in volunteers or patients.
The recently completed toxicology study conducted by Altasciences was performed under GLP standards, ensuring that the research met internationally recognized quality and regulatory requirements.
The favorable safety findings generated during the study provide Steel Therapeutics with critical evidence supporting the continued development of Fizurex™. These results will become part of the company’s regulatory package submitted to the FDA later this year.
Successful completion of this stage significantly reduces development risk while allowing the company to transition from laboratory testing into the clinical development phase.
Altasciences’ Role in the Development Program
Altasciences contributed its expertise throughout the nonclinical development process by conducting the pivotal toxicology study at its GLP-compliant research facility in Columbia, Missouri.
The company provides integrated drug development services that span preclinical research, bioanalysis, manufacturing, clinical pharmacology, and early-phase clinical development. By combining multiple development capabilities under one organization, Altasciences seeks to streamline timelines and improve coordination between research teams.
For the Fizurex™ program, Altasciences supported regulatory-focused safety assessments designed to satisfy FDA expectations while maintaining development efficiency.
Scientists and project teams from both companies worked closely together throughout the program, coordinating study design, execution, analysis, and reporting to keep the project on schedule.
This collaborative approach allowed Steel Therapeutics to efficiently generate the high-quality safety data needed to support its regulatory strategy.
Executive Perspective
Steve Mason, Co-Chief Operating Officer at Altasciences, highlighted the importance of the milestone and the collaborative relationship between the two organizations.
According to Mason, the successful completion of the toxicology study demonstrates the value of close scientific collaboration and reflects Steel Therapeutics’ commitment to developing innovative therapies for conditions where patients continue to face unmet medical needs.
He noted that producing reliable, regulatory-quality safety data is one of the most important steps in preparing an investigational therapy for human clinical testing.
Mason also emphasized that Altasciences remains focused on helping pharmaceutical and biotechnology companies accelerate promising drug candidates through the development process while maintaining scientific rigor and regulatory compliance.
Steel Therapeutics Looks Ahead
For Steel Therapeutics, the successful completion of the study represents another major achievement in the development of its lead therapeutic candidate.
Founder and Chief Executive Officer Matt Stahl said the milestone moves the company significantly closer to delivering a new treatment option for patients suffering from anal fissures.
He credited the Altasciences team for its scientific expertise, commitment, and efficient execution of the program, noting that the partnership helped the company reach this important development objective.
Stahl also indicated that the successful study positions Steel Therapeutics well as it prepares for the next stage of development, including regulatory submission and the launch of clinical trials.
Preparing for FDA Review
Steel Therapeutics plans to submit its IND application to the FDA during the third quarter of 2026.
An IND submission includes extensive documentation covering the investigational product’s manufacturing process, nonclinical safety data, pharmacology findings, and proposed clinical trial protocols.
FDA reviewers will evaluate whether the available evidence supports initiating human clinical studies.
If the agency does not identify significant safety concerns during its review period, Steel Therapeutics expects to begin first-in-human trials in 2027.
Those studies will primarily evaluate the safety, tolerability, and pharmacological characteristics of Fizurex™ while also generating preliminary information regarding its therapeutic potential.
Positive early clinical data could support subsequent Phase 2 and Phase 3 studies aimed at demonstrating the product’s effectiveness in treating anal fissures.
Addressing an Unmet Medical Need
Anal fissures remain a painful condition that affects patients across multiple age groups. Symptoms often include severe pain during bowel movements, bleeding, muscle spasms, and reduced quality of life.
Although some fissures heal with conservative management, chronic cases frequently require medical intervention. Existing treatments may include topical ointments, compounded medications, botulinum toxin injections, or surgery.
However, compounded medications can vary in quality and consistency because they are prepared individually by pharmacies rather than manufactured under standardized commercial production processes.
Steel Therapeutics believes Fizurex™ has the potential to improve treatment consistency by offering a standardized pharmaceutical product designed specifically for this indication.
If clinical development proceeds successfully and regulatory approval is eventually obtained, the therapy could provide physicians with an additional evidence-based treatment option while offering patients a convenient single-use topical administration method.
Continuing Development
The completion of the pivotal toxicology study marks a significant transition for the Fizurex™ development program, moving it from advanced nonclinical evaluation toward human clinical investigation.
For Altasciences, the collaboration highlights the company’s role in supporting biotechnology innovators through critical stages of drug development by providing integrated research services and regulatory expertise.
For Steel Therapeutics, the milestone represents continued momentum toward transforming an investigational concept into a potential commercial therapy capable of addressing an underserved medical condition.
With IND submission expected later this year and first-in-human studies planned for 2027, both organizations remain focused on advancing Fizurex™ through the next phases of development while working toward the long-term goal of bringing a standardized, clinically validated treatment option to patients living with anal fissures.
Source Link: https://www.businesswire.com/
